HaloVax Overview
- Year Founded
-
2020
- Status
-
Acquired/Merged
- Latest Deal Type
-
Out of Business
- Financing Rounds
-
2
HaloVax General Information
Description
Operator of a biotechnology company intended to develop a vaccine to prevent the Coronavirus. The company's vaccine is being designed on a validated platform to provide customized T cell immunity against COVID-19, while also allowing for rapid adaptation to potential genetic drift of the virus.
Contact Information
Website
www.halovax.comCorporate Office
- 1 Rockefeller Plaza
- Suite 1039
- New York, NY 10020
- United States
Corporate Office
- 1 Rockefeller Plaza
- Suite 1039
- New York, NY 10020
- United States
HaloVax Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
HaloVax Former Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
HaloVax FAQs
-
When was HaloVax founded?
HaloVax was founded in 2020.
-
Where is HaloVax headquartered?
HaloVax is headquartered in New York, NY.
-
What industry is HaloVax in?
HaloVax’s primary industry is Biotechnology.
-
Is HaloVax a private or public company?
HaloVax is a Private company.
-
What is HaloVax’s current revenue?
The current revenue for HaloVax is .
-
Who are HaloVax’s investors?
Rocket One and Voltron Therapeutics have invested in HaloVax.
-
When was HaloVax acquired?
HaloVax was acquired on 09-Nov-2025.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process